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ABSTRACT: We investigated the mutation spectrum of
the TANK-Binding Kinase 1 (TBK1) gene and its as-
sociated phenotypic spectrum by exonic resequencing of
TBK1 in a cohort of 2,538 patients with frontotemporal
dementia (FTD), amyotrophic lateral sclerosis (ALS), or
FTD plus ALS, ascertained within the European Early-
Onset Dementia Consortium. We assessed pathogenicity
of predicted protein-truncating mutations by measuring
loss of RNA expression. Functional effect of in-frame
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amino acid deletions and missense mutations was further
explored in vivo on protein level and in vitro by an NFκB-
induced luciferase reporter assay and measuring phospho-
rylated TBK1. The protein-truncating mutations led to
the loss of transcript through nonsense-mediated mRNA
decay. For the in-frame amino acid deletions, we demon-
strated loss of TBK1 or phosphorylated TBK1 protein.
An important fraction of the missense mutations compro-
mised NFκB activation indicating that at least some func-
tions of TBK1 are lost. Although missense mutations were
also present in controls, over three times more mutations
affecting TBK1 functioning were found in the mutation
fraction observed in patients only, suggesting high-risk al-
leles (P = 0.03). Total mutation frequency for confirmed
TBK1 LoF mutations in the European cohort was 0.7%,
with frequencies in the clinical subgroups of 0.4% in FTD,
1.3% in ALS, and 3.6% in FTD-ALS.
Hum Mutat 00:1–13, 2016. Published 2016 Wiley Periodicals,
Inc.∗∗
KEYWORDS:TANK-Binding Kinase 1; TBK1; frontotem-
poral dementia; FTD; amyotrophic lateral sclerosis; ALS;
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Introduction
Multiple lines of evidence have now strongly established that
frontotemporal lobar degeneration (FTLD) and amyotrophic lateral
sclerosis (ALS) share a commonmolecular etiology and are part of a
disease continuum. Up to 50% of frontotemporal dementia (FTD)
patients develop signs ofmotorneurondisease (MND)at some stage
in the disease course with about 15%meeting the diagnostic criteria
of ALS; conversely, over 30% of ALS patients show signs of FTD
[Lomen-Hoerth et al., 2002]. Neuropathologically, the majority of
thesepatients display accumulationofTDP-43 aggregates in affected
brain regions and motor neurons. Furthermore, common genetic
factors underlying FTLD and ALS, such as the chromosome 9 open-
reading frame 72 (C9orf72, MIM# 614260) [DeJesus-Hernandez
et al., 2011; Renton et al., 2011; Gijselinck et al., 2012], valosin
containingprotein (VCP,MIM#601023) [Watts et al., 2004; Johnson
et al., 2010], TAR DNA-binding protein (TARDBP, MIM# 605078)
[Kabashi et al., 2008; Sreedharan et al., 2008; Borroni et al., 2009;
Gelpi et al., 2014], and Fused in sarcoma RNA-binding protein
(FUS, MIM# 137070) [Kwiatkowski et al., 2009; Van Langenhove
et al., 2010] genes, are key pathological genes in both diseases. Of
these, the G4C2 repeat expansion in C9orf72 is the most frequent
genetic cause of the FTD–ALS spectrum, accounting for up to 29%,
50%,and88%ofFTD,ALS, andFTD-ALSpatient series, respectively
[Cruts et al., 2013].
Also, loss-of-function (LoF) of the TANK-binding kinase 1
(TBK1, MIM# 604834) was causally associated with ALS and FTD
[Cirulli et al., 2015; Freischmidt et al., 2015; Gijselinck et al., 2015;
Le Ber et al., 2015; Pottier et al., 2015;Williams et al., 2015]. TBK1 is
a multifunctional kinase regulating a number of cellular processes,
including the innate immune system and inflammation, autophagy,
and cell proliferation, by phosphorylating a wide range of sub-
strates [Cle´ment et al., 2008; Pilli et al., 2012; Larabi et al., 2013].
Of interest, these substrates include optineurin (OPTN) and p62,
two autophagic proteins that are also genetically implicated in the
FTD-ALS spectrum. Furthermore, TBK1 homodimerization and
autophosphorylation at the serine 172 residue is necessary for its
activation. One of the downstream effects of TBK1 activation is the
upregulation of interferon (IFN)-stimulated genes by activation of
the nuclear factor of the kappa light polypeptide gene enhancer in
B-cells (NFκB) complex.
Frameshift, out-frame, splice-site, and nonsense mutations gen-
erating premature termination codons (PTC) in TBK1 have been
demonstrated to result in LoF through loss of mutant transcript
and protein [Freischmidt et al., 2015; Gijselinck et al., 2015;
Pottier et al., 2015]. In addition to these clear pathogenicmutations,
a small number of in-frame single amino acid deletions have been
found, some of which cosegregated with disease that led to loss of
protein, whereas others did not [Freischmidt et al., 2015; Gijselinck
et al., 2015]. Furthermore, numerous rare missense mutations have
been identified, in both patient and control subjects [Cirulli et al.,
2015; Freischmidt et al., 2015; Gijselinck et al., 2015; Le Ber et al.,
2015; Pottier et al., 2015; Williams et al., 2015]. Prediction of their
pathogenic effect may be ambiguous, certainly in the absence of
supportive cosegregation. One report was able to demonstrate func-
tional deficits for a number of missense mutations by testing their
effect in vitro on the IFNβ pathway and on the interaction with
adaptor protein OPTN [Freischmidt et al., 2015], indicating that at
least some missense mutations may be disease-causing.
In the previous study, we reported the identification of TBK1
LoF mutations in a Belgian discovery cohort of FTD (n = 460),
FTD-ALS (n = 22), and ALS (n = 147) patients, yielding mutation
frequencies of 1.1% in FTD, 3.4% inALS patients, and 4.5% in FTD-
ALS [Gijselinck et al., 2015]. In the present study, we expanded the
TBK1 genetic screen with a European replication cohort of 1,755
patients with FTD (n = 1,271), ALS (n = 407), or FTD-ALS (n =
77). In addition to the protein-truncating mutations that led to
loss of transcript, we also assessed the pathogenic effect of in-frame
deletions andmissensemutations on protein level and function, the
latter using an in vitro luciferase assaymeasuring the effect ofmutant
TBK1 on NFκB activation in the IFN pathway. Taken together, this
study reports on the mutation frequency andmutation spectrum of
TBK1 in an extended European study population of 2,538 patients
with FTD (n = 1,873), ALS (n = 554), or FTD-ALS (n = 111).
Materials and Methods
European Study Population
The patient and control cohorts under study were ascertained
through the Belgian Neurology (BELNEU) consortium or the Eu-
ropean Early-Onset Dementia (EU EOD) consortium, as described
in previous studies [van der Zee et al., 2013, 2014; Gijselinck et al.,
2015; VanMossevelde et al., 2015]. DNA andmedical/demographic
information was included on 2,538 patients, comprising 1,873 pa-
tients diagnosed with FTD, 111 with concomitant FTD-ALS, and
554 patients with ALS. Patients originated from Austria, Belgium,
Bulgaria, Czech Republic, Germany, Greece, Italy, Portugal, Spain,
and Sweden (Table 1). Patients were evaluated and diagnosed with
FTD according to the Lund and Manchester group criteria [Neary
et al., 1998], and for ALS, according to the revised El Escorial cri-
teria [Brooks et al., 2000]. Clinical diagnoses of behavioral variant
FTD (bvFTD) was based on the international consensus criteria by
Rascovsky et al. (2011), andof primary progressive aphasia (PPA) on
the classification of Gorno-Tempini et al. (2011). A positive family
history was defined for index patients with first- or second-degree
relatives with symptoms of dementia or MND. In the FTD group,
34%(635/1,873)hadapositive familyhistory, in theFTD-ALSgroup
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Table 1. Descriptives of the EU EOD Patient Cohorts
FTD FTD-ALS ALS Total
EU EOD cohorts and PI 1,873 111 554 2,538
Belgium (n = 783)
Van Broeckhoven ( = Belgian discovery cohort) 460 22 147 629
Van Broeckhoven 142 12 0 154
Spain (n = 548)
Clarimon 76 7 92 175
Pastor 126 3 12 141
Ruiz 95 0 0 95
Sanchez 53 8 0 61
Gelpi 12 8 16 36
Go´mez-Tortosa 38 2 0 40
Italy (n = 442)
Borroni 165 12 24 201
IRCCS Brescia 01 110 0 0 110
Nacmias 74 5 0 79
Frisoni 48 1 0 49
Fabrizi 0 2 1 3
Germany (n = 317)
Diehl-Schmid 153 3 0 156
Ramirez 60 0 21 81
Synofzik 0 0 78 78
Danek 1 1 0 2
Portugal (n = 195)
Mendonc¸a 130 4 0 134
Santana 57 4 0 61
Bulgaria (n = 134)
Jordanova 0 2 132 134
Sweden (n = 60)
Graff 55 4 1 60
Czech Republic (n = 30)
Mateˇj 18 8 4 30
Greece (n = 26)
Fraidakis 0 1 25 26
Austria (n = 3)
Kovacs 0 2 1 3
Of the 783 Belgian patients and 1,074 Belgian controls included in the present European
study population, TBK1 mutation screening data on 629 patients and 1,044 control
individualswere previously published as part of theBelgiandiscovery cohort [Gijselinck
et al., 2015; VanMossevelde et al., 2015]. Novel patients and control subjects reported in
this study are part of the European replication cohort. Together, the Belgian discovery
cohort and the European replication cohort constitute the European study population.
P.I., principle investigator.
29% (32/111) and in the ALS group 8% (46/554). As control group,
2,183 age- and origin-matched European control individuals, with
no personal or family history of neurodegenerative or psychiatric
diseases, were included.
Of the 783Belgian patients and 1,074Belgian controls included in
the present European study population (Table 1), TBK1 mutation
screening data on 629 patients and 1,044 control individuals was
generated and published as part of the Belgian discovery cohort
[Gijselinck et al., 2015; Van Mossevelde et al., 2015]. Novel patients
(n = 1,755) and control subjects (n = 1,109) reported in this study
are part of the European replication cohort. Together, the Belgian
discovery cohort and the European replication cohort constitute the
European study population (Table 1).
For all participants, informed consent for participation in the
genetic studies was obtained according to sampling protocols that
were approved by the local Ethics Committees of the collaborating
medical centers. The protocols for the genetic studies were approved
by the Ethics Committee of the University of Antwerp, Belgium.
Exonic Resequencing
All coding exons of TBK1 (NM 013254.3) were sequenced on
a MiSeq platform using the MiSeq V2 chemistry (Illumina, San
Diego, CA), except for exon 4, which was sequenced by Sanger
sequencing using the BigDye R© Terminator Cycle Sequencing kit
v3.1 (Applied Biosystems, Foster City, CA). Detailed technical
procedures were previously described [Gijselinck et al., 2015].
Reported variants follow cDNA numbering according to refer-
ence sequence NM 013254.3. In addition, for intronic variants, the
genomic reference sequence NC 000012.12 was used. Nucleotide
positions refer to cDNA sequence and nucleotide numbering uses
+1 as the A of the ATG translation initiation codon in the reference
sequence,with the initiation codonas codon1. Proteinnumbering is
given according to reference sequence NP 037386.1. Variants iden-
tified in this study have been submitted to the Alzheimer Disease
& Frontotemporal Dementia Mutation Database (AD&FTDMDB,
http://www.molgen.vib-ua.be/FTDMutations) and Locus Specific
Database [Cruts et al., 2012].
Transcript Analysis
When the required biomaterials were available, transcript
analysis was performed for patients with a TBK1 mutation
(Fig. 1). For the c.288delT (p.Val97Phefs∗2) and the c.1340+1G>A
(p.Ala417∗) carriers, total RNAwas isolated fromwhole blood using
the PAXgene Blood RNA kit (PreAnalytiX; Qiagen, Valencia, CA) in
accordance with the manufacturer instructions. First-strand cDNA
was synthesized from total RNA with random hexamers primers
using the Invitrogen ThermoScript RT-PCR kit (Invitrogen,
Carlsbad, CA). For transcript analysis of the c.235 237delACA
(p.Thr79del) and c.379C>T (p.Arg127∗) carriers, total RNA was
extracted from blood mononuclear cells (p.Arg127∗) or frontal
cortical brain tissue (p.Thr79del) from the carriers. First-strand
cDNAwas synthesizedwith oligodT and randomhexamers primers,
using the SuperScript III First-Strand Synthesis System for RT-PCR
kit (Invitrogen). cDNA of these samples was amplified using
the universal amplification protocol (Applied Biosystems). For
p.Val97Phefs∗2, exon 4 was amplified with flanking PCR primers
positioned in exons 3 and 5. For p.Ala417∗, predicted to lead to exon
11 skipping, cDNA was amplified with primers positioned in exons
10 and 13. For p.Arg127∗, exon 5 was amplified with PCR primers
in exon 3 and exon 6. All PCR products were Sanger sequenced to
evaluate whether the mutant transcript was present based on the
coding mutation and whether alternative transcripts were formed.
Genotypes of cDNA sequences were compared with genomic DNA
sequences. Primer sequences will be provided upon request.
For quantification of the transcripts created by the p.Thr79del
mutation, semiquantitative real-time PCR (qPCR) was performed
using SYBR Green assays on the ViiATM 7 Real-Time PCR System
(Applied Biosystems). A qPCR amplicon was designed, spanning
exons 19 and 20 (primers 5’- CATGACCCCAATTTATCCAAGTTC-
3’ and 5’- CATCTCTTCCTTTAATTTCTTCATACCA-3’), detecting
the TBK1 refgene transcript variant NM 013254 using Primer-
Express Software (Applied Biosystems) and quantified against
three housekeeping genes, HPRT, GAPDH, and SDHA. Relative
expression levels were calculated by comparing normalized quan-
tities between patient and control samples using qbase+ software
(Biogazelle, Ghent, Belgium).
Protein Analysis
Protein lysates from the TBK1 p.Thr79del carrier and control
frontal cortex tissue were prepared forWestern blot with 0.1%RIPA
and sonicated on ice, cleared at 20,000 g for 15min at 4°Cand super-
natants used for immunoblotting (Fig. 1). Protein concentrations
were measured by a BCA assay (Pierce, Rockford, IL), and 30 μg of
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Figure 1. Transcript and protein analysis of TBK1 LoF and single amino acid deletion mutations. A: gDNA and cDNA sequence traces around
the c.288delT (p. Val97Phefs∗2) mutation, showing reduced expression of the mutant transcript on cDNA extracted from blood. B: gDNA and cDNA
sequence traces around the c.379C>T (p.Arg127∗) mutation, showing the absence of the mutant transcript on cDNA extracted from blood. C: Sizing
of cDNA fragments generated with primers in TBK1 exon 10 and exon 13 of the c.1340+1G>A (p.Ala417∗) carrier on cDNA extracted from blood.
Sequence traces from the low-expressed aberrant transcript demonstrates skipping of exon 11. D: Transcript and protein analysis on brain frontal
cortex from the c.235_237delACA (p.Thr79del) carrier and four age-matched control brains. The graph on the left shows the relative expression in
the patient sample (blue) compared with the control samples (black) measured by quantitative real-time PCR (qRT-PCR). In the middle, Western
blot analysis is shown of protein extracts from the patient carrier compared with control individuals. The upper band represents TBK1 (84 kDa)
and the lower band represents the housekeeping protein GAPDH (37 kDa). The graph on the right shows the quantification in the patient sample
(blue) and control samples (black) of the TBK1 signal normalized to the signal of GAPDH. Error bars represent the SD. E: Western blot analysis of
phosphorylated TBK1 (Ser172, p-TBK1) (upper band, 84 kDa) in HEK293T cells overexpressing the in-frame single amino acid deletions (p.Thr79del,
p.Asp167del, and p.Glu643del) compared with wild type, relative to GAPDH (lower band, 37 kDa). Mock and kinase dead (p.Ser172Ala, KD) were
used as negative control. cDNA numbering according to reference sequenceNM_013254.3, in addition, for intronic variants, the genomic reference
sequence NC_000012.12 was used. Nucleotide positions refer to cDNA sequence and nucleotide numbering uses +1 as the A of the ATG translation
initiation codon in the reference sequence, with the initiation codon as codon 1. Protein numbering according to reference sequence NP_037386.1.
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Table 2. TBK1 Predicted LoF Mutations in the European Study Population
FTD FTD-ALS ALS
cDNA Predicted protein n = 1,873 n = 111 n = 554 Cohorts of the European study population
Protein-truncating mutations leading to loss of transcript
c.4C>T p.Gln∗2 1 Belgian discovery cohort
c.86delA p.Lys29Argfs∗15 1 European replication cohort
c.288delT p.Val97Phefs∗2 1 European replication cohort
c.349C>T p.Arg117∗ 1 European replication cohort
c.379C>T p.Arg127∗ 1 European replication cohort
c.992+1G>T p.Gly272 Thr331del 1 Belgian discovery cohort
c.1192delT p.Ser398Profs∗11 1 Belgian discovery cohort
c.1335G>A p.Trp445∗ 1 European replication cohort
c.1340+1G>A p.Ala417∗ 1 European replication cohort
c.1385 1388delCAGA p.Thr462Lysfs∗3 1 European replication cohort
c.1551 1552insTT p.Ser518Leufs∗32 1 Belgian discovery cohort
In-frame deletions leading to loss-of-protein or protein function
c.235 237delACA p.Thr79del 1 European replication cohort
c.499 501delGAT p.Asp167del 1 Belgian discovery cohort
c.1927 1929delGAA p.Glu643del 3 1 2 Belgian discovery cohort
Predicted in-frame deletions with unknown effect
c.228+1G>A p.Lys30 Glu76del 1 European replication cohort
c.992+4 992+7delAGTA p.Gly272 Thr331del 1 European replication cohort
All listed mutations were absent from 2,183 screened control individuals and dbSNP build 138. The respective cohorts of the European study population in which mutations
were identified are indicated in the last column. Mutations and carriers identified in the Belgian discovery cohort were previously published by our group [Gijselinck et al., 2015;
Van Mossevelde et al., 2015]. Novel mutations and carriers reported in this study are part of the European replication cohort. cDNA numbering was according to the reference
sequence NM_013254.3. In addition, for intronic variants, the genomic reference sequence NC_000012.12 was used. Nucleotide positions refer to cDNA sequence and nucleotide
numbering uses +1 as the A of the ATG translation initiation codon in the reference sequence, with the initiation codon as codon 1. Protein numbering according to reference
sequence NP_037386.1.
protein were separated on 4%–12% Nupage Bis–Tris gels (Invitro-
gen), electroblottedonto aPVDFmembrane (HybondP;Amersham
Biosciences, GE Helthcare, Little Chalfont, UK), and probed with
a monoclonal antibody against TBK1 (Abcam, Cambridge, MA;
1:1,000, 84 kDa). Immuno-detection was performed with specific
secondary antibodies conjugated to horseradish peroxidase and
the ECL-plus chemiluminescent detection system (Amersham Bio-
sciences). TBK1 signal intensities were quantified against GAPDH
(Genetex, Irvine, CA; 1:10,000, 37 kDa), using ImageQuantTL
software (GE Healthcare Life Sciences, Little Chalfont, UK).
TBK1 Cloning and Overexpression in HEK293T Cells
TBK1 plasmids containing amissensemutation or a single amino
acid deletionwere generated by in vitromutagenesis using theKAPA
HiFi HotStart DNA polymerase (Kapa Biosystems, Wilmington,
MA) starting from the TBK1 wild-type gateway pDONR vector
(NM 013254.3) (GeneCopoeia, Rockville, MD). The p.Ser172Ala
mutant (kinase dead) generating a TBK1 protein lacking kinase
activity, and the mock plasmid containing no TBK1, were used
as negative controls. The gateway-compatible pCR3 vector (Life
Technologies, Carlsbad, CA) was used as expression vector.
Each TBK1 plasmid was transiently transfected in HEK293T cells
using Lipofectamine 2000 (Life Technologies). Protein lysates of
these TBK1 overexpression cells were used forWestern blotting with
an antibody against TBK1 (Abcam; 1:1,000, 84 kDa) and GAPDH
(Genetex; 1:10,000, 37 kDa). Autophosphorylation activity of the
single amino acid deletions was determined byWestern blot analysis
with p-TBK1 antibody (phospho S172) (Abcam; 1:500, 84 kDa).
NFκB Reporter Assay
Each TBK1 plasmid was transiently transfected in human embry-
onic kidney cells (HEK293T) using X-tremeGENE 9 DNA Trans-
fection Reagent (Sigma–Aldrich, St Louis, MO), together with the
NFκB luciferase reporter vector (Affymetrix, Santa Clara, CA) con-
taining an inducible Firefly luciferase reporter gene to monitor
the activation of the NFκB signal transduction pathway and the
pTK-GLuc plasmid that encodes the Gaussia luciferase gene (New
England Biolabs, Ipswich, MA) for normalization. Firefly luciferase
activities (LAF) and Gaussia luciferase activities (LAG) were mea-
sured in fivefold by the use of a Dual-Glo Luciferase Assay System
(Promega, Madison, WI) and a BioLux Gaussia Luciferase Assay
Kit (New England Biolabs) on a Veritas Microplate Luminome-
ter (Promega). To correct for transfection efficiency and DNA up-
take, the relative luciferase activity (RLA) was calculated as RLA =
LAF/LAG. This experiment was repeated three times. Differences in
relative luciferase activities between mutant and wild-type TBK1
plasmids were calculated by a linear mixed model using the statisti-
cal packages lme4 and nlme in R and corrected for multiple testing
using Bonferroni correction.
Neuropathology of TBK1 p.Thr79del Carrier
Neuropathological work-up was performed at the Neurological
Tissue Bank of the Biobanc-Hospital Clinic-IDIBAPS (Barcelona,
Spain), according to standardized procedures. In brief, fragments of
frontal cortex and cerebellum were immediately frozen at –80°C,
whereas the remaining brain tissue was fixed in 10% buffered
formaldehyde solution for 4 weeks. For histopathological evalua-
tion, 5μmthick sectionswere cut from formalin-fixed and paraffin-
embedded tissue from multiple brain areas including frontal,
temporal, parietal and occipital cortices, motor cortex, anterior cin-
gulate gyrus, anterior and posterior basal ganglia, anterior, medial
and posterior thalamic nuclei, hippocampus and parahippocampal
gyrus, amygdala, n. basalis Meynert, midbrain, pons, medulla ob-
longata, cerebellar vermis, and dentate nucleus, as well as cervical,
thoracic, and lumbar segments of spinal cord.
Sections were stained with hematoxylin-eosin, Luxol fast blue,
and for immunohistochemistry using the following monoclonal
(mc) and polyclonal (pc) primary antibodies on an automated
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immunostainer (DAKO autostainer plus; DAKO, Glostrup, Den-
mark) after heat- or chemically induced epitope retrieval with
formic acid: anti-bA4-amyloid (DAKO; mc, clone 6F/3D, dilution
1:400), antiphosphorylated tau (Thermo Scientific, Rockford, IL;
mc, clone AT8, dilution 1:200), antiubiquitin (DAKO; pc, dilution
1:400), anti-alpha-synuclein (Novocastra, Newcastle, UK;mc, clone
KM51, dilution 1:500), anti-TDP-43 (Abnova, Taipei, Taiwan; mc,
clone 2E2-D3, dilution 1:500), antineurofilaments (Novocastra;
clone RT97, dilution 1:800), anti-RD3 (Millipore, Temecula, CA;
mc, clone 8E6/C11, dilution 1:1,000), anti-RD4 (Millipore; mc,
clone 1E1/A6, dilution 1:50), anti-alpha-internexin (Invitrogen;
mc, clone 2E3, dilution 1:800), and anti-alpha-B-crystallin
(Novocastra; mc, clone G2JF, dilution 1:100).
Statistical Analysis
Missense mutation frequencies were compared between patients
and controls using a Fisher exact test. Significance level was set at
P < 0.05.
Results
Protein-Truncating Mutations
In the Belgian discovery cohort, we have reported four TBK1
LoF mutations (Table 2) [Gijselinck et al., 2015]. In this study,
massive parallel exonic resequencing of the TBK1 coding region was
performed in the EU replication cohort of 1,755 patients, among
which 1,271 FTD, 407 ALS patients, and 77 FTD-ALS, together
with 1,109 European control individuals. In the patients, seven
additional predicted LoF mutations were identified, including
three small out-frame deletions, three nonsense mutations,
and one splice donor-site mutation (Table 2). These mutations
introduce a PTC and are expected to result in loss of transcript
due to nonsense-mediated mRNA decay (NMD). No PTC or
splice-site mutations were observed in the control subjects. We
had already confirmed NMD for two PTC mutations, c.1192delT
(p.Ser398Profs∗11) and c.1551 1552insTT (p.Ser518Leufs∗32)
[Gijselinck et al., 2015]. In addition, for the predicted in-frame
exon-skipping mutation c.992+1G>T (p.Gly272 Thr331del) af-
fecting exon 8, we demonstrated cryptic splicing activation and
reduction of transcript and protein in brain [Gijselinck et al.,
2015]. In the present study, we demonstrated NMD for three more
mutations. For c.288delT (p.Val97Phefs∗2), we showed a strong
but incomplete reduction of the mutant transcript, for c.379C>T
(p.Arg127∗) a complete absence of the mutant transcript (Fig. 1A
and B). For the previously reported splice donor-site mutation in
intron 11 (c.1340+1G>A), we confirmed out-of-frame skipping of
exon 11 leading to a PTC (p.Ala417∗) (Fig. 1C) [Freischmidt et al.,
2015]. For three of the mutation carriers in the EU replication
cohort, c.288delT (p.Val97Phefs∗2), c.1340+1G>A (p.Ala417∗),
and c.1385 1388delCAGA (p.Thr462Lysfs∗3), we identified an
additional affected relative with the mutation.
In addition to these proven loss-of-transcript mutations, we
identified two novel predicted in-frame exon-skipping mutations.
These splice donor-site mutations in intron 3 (c.228+1G>A) and
intron 8 (c.992+4 7delAGTA) are predicted to result in a deletion of
47 (p.Lys30 Glu76del) and 60 amino acids (p.Gly272 Thr331del).
No cells or tissues from the carriers were available for transcript
and protein analysis; therefore, we were unable to demonstrate the
effect of these two mutations, and as a consequence, they were not
considered further when calculating TBK1mutation frequencies.
In-Frame Deletions
We have observed two in-frame, single amino acid dele-
tions in the BE discovery cohort and one additional in-frame
deletion in the EU replication cohort (Table 2). All three,
c.235 237delACA (p.Thr79del), c.499 501delGAT (p.Asp167del),
and c.1927 1929delGAA (p.Glu643del), were absent from control
subjects, and no other amino acid deletion mutations were ob-
served in the control cohort. The p.Thr79del mutation was iden-
tified in a Spanish patient. The two other mutations, p.Asp167del
and p.Glu643del, had been detected in Belgian patients [Gijselinck
et al., 2015]. The p.Glu643del mutation was present in one index
patient and five affected relatives and an additional five unrelated
index patients [Gijselinck et al., 2015; Van Mossevelde et al., 2015].
In contrast to the protein-truncating mutations, the p.Glu643del
mutation did not affect transcript levels but produced 50% loss
of TBK1 protein in vivo [Gijselinck et al., 2015]. In this study, we
obtained comparable results for the Spanish mutation, p.Thr79del,
with loss of expression only at the protein level observed in brain
(Fig. 1D). The p.Asp167del behaved differently. Here, TBK1 protein
expression in brain was preserved [Gijselinck et al., 2015]. In vitro
TBK1 protein expression of p.Thr79del and p.Glu643del mutations
overexpressed in HEK293T cells was reduced but not completely
absent (Supp. Fig. S1), whereas phospho-TBK1 was completely ab-
sent for p.Thr79del and p.Asp167del, and almost completely absent
for p.Glu643del (Fig. 1E).
We further investigated the effect of the three in-frame deletions
onNFκBactivation, using anNFκB in vitro luciferase reporter assay.
Results showed that all three amino acid deletionmutations severely
disrupted NFκB activation (Fig. 2). The two single amino acid dele-
tions located in the KD, p.Thr79del and p.Asp167del, resulted in a
complete loss of NFκB activation. The p.Glu643del mutation that
maps to the scaffold dimerization domain (SDD; residues 408–657)
[Larabi et al., 2013], showed a highly significant reduction of about
70%.
Taken together, the in vivo protein expression and in vitro ex-
periments demonstrated that, in addition to the protein-truncating
LoF mutations, in-frame deletions also lead to TBK1 LoF through
loss-of-protein and/or protein function.
In conclusion, in the European replication cohort, we identi-
fied seven LoF protein-truncating mutations and one LoF in-frame
deletion mutation in a total of eight index patients, resulting in
a mutation frequency of TBK1 LoF mutations of 0.5% (8/1,755)
overall and 0.2% in FTD patients (3/1,271), 0.5% in ALS patients
(2/407), and 3.9% in FTD-ALS patients (3/77). Meta-analysis of the
Belgian discovery cohort and the EU replication cohort resulted in a
total mutation frequency for TBK1 LoFmutations in the overall Eu-
ropean study population of 0.7% (19/2,538), comprising 0.4% FTD
patients (8/1,873), 1.3% ALS patients (7/554), and 3.6% FTD-ALS
patients (4/111).
TBK1 Missense Mutations
In the present study, we also investigated the prevalence and
functional effect of missense mutations in the European study pop-
ulation. In the patient cohort, we identified 25 missense mutations
in 26 patients, of which 16 were found only in patients (Table 3).
In the control cohort, we identified 15 missense mutations in 16
individuals that were absent in patients (Table 3). We tested all 40
missense mutations using the NFκB reporter assay (Table 3; Fig. 2).
In the patient-only group, we found seven missense mutations
in seven patients that showed an effect on NFκB induction (7/16
carriers, 44%). Six missense mutations showed a70% decrease in
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Figure 2. Impact of mutant TBK1 on NFκB activity in the IFN pathway. Graphical representation of the mean NFκB-induced luciferase activity
of identified in-frame amino acid deletions and missense mutations found in patients-only, shared by patients and controls, and in controls-only,
normalized to the mean signal from wild type. Luciferase activities were measured in at least three independent experiments and measured five
times per experiment. The different domains are indicated in different colors as shown in the figure legend. WT, wild type TBK1 vector; Mock,
empty vector containing no TBK1; S172A-KD, p.Ser172Ala TBK1 kinase dead mutation. Mock and S172A-KD were used as negative controls. Error
bars depict standard deviation and asterisks above the bars indicate significant difference from the wild-type level after Bonferroni correction
(P<0.001). Protein numbering according to reference sequence NP_037386.1.
NFκB activation as compared with wild-type TBK1, of which the
c.281T>C (p.Leu94Ser) mutation showed a complete loss. These six
missense mutations were located in the KD of TBK1. To a lesser
extent but still significant, the c.1252A>G (p.Ile418Val) mutant in
the SDD decreased NFκB induction by 45%.
In the group of missense mutations present in both patients and
controls, just one missense mutation c.871A>G (p.Lys291Glu), also
located in the KD domain and present in one patient and two
control subjects, showed a significant decrease in NFκB induction
(3/25 carriers, 12%).
Of the 15 missense mutations that were observed in control
subjects only, two mutations located in the KD protein domain
showed a significant reduction, with a complete loss for c.47G>A
(p.Gly16Asp) and a 25% reduction for c.428G>A (p.Arg143His)
(2/16 carriers, 13%).
When comparing the prevalence of missense mutations with
a compromised NFκB activation capacity (= functional missense
mutations) in patients and controls, we observed about twice as
many in patients. In the patients, eight carriers of a functional and
therefore potentially pathogenic missense mutation were identified
(8/2,538, 0.32%) as compared to four in control subjects (4/2,183,
0.18%) (P = 0.40). Although functional missense mutations were
identified in the patient-only, the patient and control, as well as
the control-only group, over three times as many carriers of func-
tional missense mutations were counted in the patient-only group
(7/16, 44%) versus the group of carriers of missense mutations
that were also observed in the control population (5/41, 12%)
(P = 0.025).
Phenotypic Characteristics of TBK1Mutation Carriers
Demographic, genetic, and clinical features of the pathogenic and
possibly pathogenic TBK1 mutation carriers (protein-truncating
mutations, in-frame deletions, and functional missense mutations)
are summarized in Table 4.
Eleven of the 19 index patients with a TBK1 LoF mutation had
FTD as presenting clinical phenotype. In this subset of patients, nine
developed FTD without clinical signs of MND. In the years follow-
ing first diagnosis, two patients developed ALS and another patient
progressed into a corticobasal syndrome (CBS). Eight patients pre-
sented first with ALS, of which one showed concomitant cognitive
deterioration suffering from a severe memory disorder and visuo-
constructional deficits but no specification of the dementia diagno-
sis was possible. Of all patients diagnosed with ALS (n = 10), four
had bulbar onset and one had spinal onset. In five ALS patients, the
site of onset was not specified. Of all FTD (or unspecified dementia)
patients (n = 12), the majority was diagnosed with bvFTD (8/12).
Three others presented with a language variant of FTD, progressive
nonfluent aphasia (PNFA) or PPA. The remaining patient received a
diagnosis of unspecified dementia (together with ALS). Mean age at
onset in all 19TBK1 LoF carriers was 63.9± 7.8 years (range 48–78).
Of the 12 patients that died, mean age at death was 65.5 ± 8.9 years
(range 50–77) with an average disease duration of 42 ± 40 months
(range 6–136).
Neuropathological examination was performed in three of the
deceased patients. The patient with the p.Val97Phefs∗2 mutation
displayed pure MND with TDP-43 inclusions. The carrier of the
p.Ala417∗ mutation showed mild TDP-43 proteinopathy in af-
fected brain regions (type B). Neuropathological investigation in
the p.Thr79del carrier confirmed the diagnosis of FTLD-MND-
TDP (type B), but additional argyrophilic grain disease stage III was
noted (Fig. 3).
In the eight functionalmissensemutation carriers, four presented
first with FTD, of whom one developed concomitant ALS, and
four presented with ALS only. Again, in the FTD patients, bvFTD
was the predominant subtype (3/4). In the ALS patients, two had
spinal onset and two had bulbar onset. Average onset age was low at
46.6 ± 7.4 years (range 34–57). The three patients that passed away
died at relatively young ages of 43, 59, and 61 years (average age at
death 54.3 ± 9.9 years).
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Table 3. TBK1Missense Mutations in the European Study Population
FTD FTD-ALS ALS Controls
cDNA
Predicted
protein Domain dbSNP NFκB activity n = 1,873 n = 111 n = 554 n = 2,183
Missense mutations found in patients only
c.188A>G p.Asn63Ser KD - n.s. 1
c.281T>C p.Leu94Ser KD - Reduced 1
c.362G>A p.Gly121Asp KD - Reduced 1
c.427C>T p.Arg143Cys KD - Reduced 1
c.687G>T p.Arg229Ser KD - Reduced 1
c.731G>T p.Gly244Val KD - Reduced 1
c.737T>C p.Ile246Thr KD - Reduced 1
c.794T>C p.Val265Ala KD - n.s. 1
c.812G>T p.Arg271Leu KD - n.s. 1a
c.1057A>G p.Ile353Val ULD - n.s. 1
c.1190T>C p.Ile397Thr linker - n.s. 1
c.1217A>G p.Tyr406Cys linker - n.s. 1
c.1252A>G p.Ile418Val SDD rs138839127 Reduced 1
c.1544T>C p.Ile515Thr SDD rs151225287 n.s. 1a
c.1612C>T p.His538Tyr SDD - n.s. 1
c.1717C>G p.Arg573Gly SDD - n.s. 1
Missense mutations found in patients and control subjects
c.217A>G p.Ile73Val KD - Increased 2 1
c.550A>G p.Met184Val KD - n.s. 1 1
c.871A>G p.Lys291Glu KD rs34774243 Reduced 1a 2
c.964C>T p.His322Tyr ULD rs145905497 n.s. 1a 1
c.1179A>G p.Ile393Met linker - n.s. 1 1
c.1603G>A p.Ala535Thr SDD rs199905735 n.s. 1a 1
c.1709A>G p.Lys570Arg SDD - n.s. 1 2
c.1792A>G p.Met598Val SDD - n.s. 1 2
c.1957G>C p.Glu653Gln SDD rs144370662 n.s. 1 4
Missense mutations found in control subjects only
c.40A>G p.Ile14Val KD - n.s. 1
c.47G>A p.Gly16Asp KD - Reduced 1
c.149A>C p.Asp50Ala KD - Increased 1
c.167T>C p.Phe56Ser KD - n.s. 1
c.428G>A p.Arg143His KD - Reduced 1
c.944C>T p.Ser315Leu ULD rs369620088 n.s. 1
c.1037T>C p.Ile346Thr ULD - n.s. 1
c.1040C>T p.Ser347Phe ULD - n.s. 1
c.1150C>T p.Arg384Trp ULD - n.s. 1
c.1364A>G p.Asn455Ser SDD - Increased 1
c.1366G>C p.Glu456Gln SDD - n.s. 1
c.1538G>A p.Gly513Glu SDD - n.s. 1
c.1796C>T p.Thr599Met SDD - n.s. 1
c.1952C>T p.Thr651Ile SDD - n.s. 1
c.2170C>T p.Arg724Cys CTD rs185524052 n.s. 2
TBK1 functional domains according to Larabi et al. (2013): KD, kinase domain (residues 1–307); ULD, ubiquitin-like domain (residues 309–384); linker; linker (residues 385–407);
SDD, scaffold dimerization domain (residues 408–657); CTD, C-terminal domain (residues 657–745). Results of the in vitro NFkB luciferase reporter assay measuring the effect of
mutant TBK1 on NFκB activity are listed (see also Fig. 2). Reduced indicates that a significant reduction in luciferase activity was measured; increased indicates that a significant
increase in luciferase activity was measured. n.s., no significant change in luciferase activity was measured.
aRefers to mutations and carriers identified in the Belgian discovery cohort that were published earlier [Gijselinck et al., 2015]. cDNA numbering according to reference sequence
NM_013254.3. Nucleotide positions refer to cDNA sequence and nucleotide numbering uses +1 as the A of the ATG translation initiation codon in the reference sequence, with
the initiation codon as codon 1. Protein numbering was according to the reference sequence NP_037386.1.
Neuropathology of the p.Thr79del Mutation Carrier
Macroscopic evaluation showed a moderate and temporally ac-
centuated brain atrophy with an unfixed brain weight of 1,340 g. On
histological examination (Fig. 3), neuronal loss, reactive astrogliosis,
and microglial activation were observed predominantly involving
themedial temporal lobe.Abundant andwidespreadneuronalTDP-
43 protein inclusions were detected in neurons of the limbic system
including amygdala, entorhinal, and transentorhinal region, hip-
pocampus (dentate gyrus andCA1 sector), cingulate cortex, inferior
temporal cortex, and in themotor cortex,with only few inclusions in
frontal and parietal cortex, in basal ganglia and thalamus, and brain-
stem nuclei. Type of inclusions varied and comprised compact and
ring-like neuronal cytoplasmic inclusions that were observed pre-
dominantly, but not exclusively, in superficial cortical layers and also
throughout the cortex. Only very isolated dystrophic neurites were
detected.Diffuse granular cytoplasmic immunoreactivity (neuronal
"preinclusions") was frequently seen in middle-sized neurons of
frontal and temporal cortex, limbic system, basal ganglia, brainstem,
and spinal cord. Skein-like inclusionswere evident inmotorneurons
of the anterior horn of the spinal cord, but also in motor neurons of
the hypoglossal nucleus, pigmented neurons of the substantia nigra,
and few striatal neurons. Frequent oligodendroglial inclusions were
detected both in white matter and gray matter (arrows). Involve-
ment of upper motor neurons was appreciated, and there was florid
corticospinal tract degeneration showing myelin and axonal loss,
and abundant CD68-positive macrophages, whereas lower motor
neurons of anterior horns of spinal cord were moderately affected.
The distribution pattern of pathology was most concordant with
FTLD type B according to the current FTLD consensus classification
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Table 4. Clinical and Pathological Phenotype of Patients Carrying a TBK1 LoF Mutation or Possibly Pathogenic Missense Mutation
Mutation Origin Gender
Clinical
diagnosisa Subtypeb
Family
history
Age at onset
(years)
Age at last
examina-
tion/death
(years)
Disease
duration
(months)
Additional
information
Truncating mutations
p.Gln∗2c Spanish Female FTD bvFTD 56 60 >53
p.Lys29Argfs∗15 German Male FTD PNFA + PSP 73 †77 48
p.Val97Phefs∗2 Swedish Male ALS + 62 †63 MND-TDP
p.Arg117∗ Italian Male FTD bvFTD + 67 †74 86
p.Arg127∗ German Female ALS Bulbar 70 Alive
p.Trp445∗ Spanish Female FTD + CBS PNFA/agramatic
variant
78 84 >72
p.Gly272 Thr331delc Belgian Male FTD bvFTD + 48 †50 29
p.Ser398Profs∗11c Belgian Male ALS Bulbar + 59 Alive >75
p.Ala417∗ Swedish Female FTD bvFTD + 68 †71 27 FTLD-TDP type B
p.Thr462Lysfs∗3 German Male ALS + D + 74 †75 11 LMN>>UMN
p.Ser518Leufs∗32c Belgian Female ALS + 64 †64 6
In-frame deletions
p.Thr79del Spanish Male FTD + ALS bvFTD + bulbar 56 †58 18 FTLD-MND-TDP
type B +
argyrophylic
grain disease
(stage III)
p.Asp167delc Belgian Male ALS 60 †61
p.Glu643delc Belgian Female FTD + ALS bvFTD + spinal + 62 †74 136
p.Glu643delc Belgian Female FTD bvFTD + 64 Alive >109
p.Glu643delc Belgian Male ALS Bulbar + 51 †53 20
p.Glu643delc Belgian Male ALS 63 †66
p.Glu643delc Belgian Male FTD PPA + 70 †73 42
p.Glu643delc Belgian Female FTD bvFTD 69 Alive >99
Functional missense mutations
p.Leu94Ser Bulgarian Male ALS Spinal + 44 55 >120 Slow disease
progression
p.Gly121Aspc Spanish Male ALS Spinal 34 39 >60 Slow disease
progression
p.Arg143Cys German Male FTD bvFTD 45
p.Arg229Ser German Male ALS 47
p.Gly244Val Portuguese Female FTD + ALS Bulbar + 41 †43 C9orf72 repeat
expansion carrier
p.Ile246Thr German Female ALS Bulbar 57 †59
p.Lys291Gluc Belgian Male FTD bvFTD + 52 †61
p.Ile418Val Portuguese Female FTD bvFTD + 53 54
aPresenting diagnosis or symptoms are listed first.
bClinical subtype is given where documented. In FTD, the subtypes behavioral variant FTD (bvFTD), primary progressive aphasia (PPA), progressive nonfluent aphasia (PNFA),
semantic dementia (SD), and progressive supranuclear palsy (PSP) are specified where documented. In ALS, spinal or bulbar onset is specified where documented.
cRefers to mutation carriers identified in the Belgian discovery cohort that were published earlier [Gijselinck et al., 2015; Van Mossevelde et al., 2015].
CBS, corticobasal syndrome; MND, motor neuron disease; LMN, lower motor neuron symptoms; UMN, upper motor neuron symptoms; D, unspecified dementia. +, a positive
family history was documented.
[Mackenzie et al., 2011]. In addition, concomitant argyrophilic grain
pathology (AgD) was observed. This was characterized by the pres-
ence of hyperphosphorylated tau (AT8) and four-repeat tau-positive
grains in amygdala, entorhinal and transentorhinal cortex, CA1
sector of the hippocampus, and cingulum, along with frequent pre-
tangles and neuropil threads, tau-positive oligodendroglial coiled
bodies in medial temporal white matter, bush-like astrocytes, and
ballooned neurons in amygdala corresponding to stage III according
to Saito et al. (2004).
Discussion
In the pursuit of the missing heritability of the FTD-ALS spec-
trum, TBK1 haploinsufficiency was recently put forward as a novel
disease mechanism. Classical LoF mutations include nonsense and
frameshift mutations that lead to mutant transcripts containing a
PTC,which are degraded byNMDresulting in a 50% loss of protein.
In addition to loss of transcript, several other possibilities can lead to
loss–of-protein or protein function. For example, deletions of one or
more key amino acids due to small in-frame indels or in-frame exon
skipping and missense mutations can affect the catalytic function
or the stability of the protein. In the present study, we investigated
the full mutation spectrum of TBK1 and its associated phenotypic
spectrum in a large study population of 2,538 European FTD and
ALS patients. In addition to protein-truncating LoF mutations, the
functional effect of in-frame amino acid deletions and missense
mutations was further explored in vivo on protein level and in vitro
by an NFκB-induced luciferase reporter assay as functional readout
for TBK1 activity.
In total, we identified 11 index patients carrying a TBK1
protein-truncating mutation (Table 2). Nine mutations were
nonsense or frameshift mutations, of which five, (c.86delA
(p.Lys29Argfs∗15), p.Val97Phefs∗2, p.Arg127∗, c.1335G>A
(p.Trp445∗), p.Thr462Lysfs∗3), are reported here for the first time.
Multiple studies have demonstrated that PTC mutations in TBK1
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Figure 3. Neuropathology features of the FTD-ALS patient with the TBK1 p.Thr79del mutation. Severe neuronal loss, gliosis, and loosening
of the neuropil are observed in entorhinal and transentorhinal region (lower image) as compared with relatively well-preserved frontal cortex
(upper image) (HE) (A). Abundant TDP-43 protein aggregates in neurons and oligodendroglial cells (B), better seen in (C) at higher magnification
(arrows). Hippocampal dentate gyrus showssomegranular neurons lacking physiological nuclear immunoreactivity but shifting towardpathological
inclusions in the cytoplasm (D). Morphological spectrum of neuronal cytoplasmic inclusions (E–J), seen as compact bodies (E), diffuse granular
cytoplasmic immunoreactivity or “preinclusion” type (F), skein-like inclusions (G, inset), compact ring-like inclusions (H), or a combination of diffuse
cytoplasmic and compact in the same motor neuron (I). Signs of corticospinal tract degeneration at the level of the spinal cord with marked
reduction of axonal density as shown by antineurofilament immunohistochemistry (K, inset shows regular density of axons for comparison), and
increased macrophagic activity (L, anti-CD68 immunohistochemistry, inset shows regular density of CD68+ cells in the spinal cord for comparison).
Neuropathological features of concomitant argyrophilic grain pathology (M–P). Ballooned cells are seen in amygdala (M) and are nicely stained
by hyperphosphorylated tau (AT8, inset). Moreover, frequent hpTau-positive grains, mainly composed of four-repeat tau isoforms, are detected in
the limbic system (N, CA1 sector is shown), and represent enlargements/verrucosities of dendritic spines (N, inset). Oligodendroglial coiled bodies
(O) and bush-like astrocytes (P) accompany the full picture.
lead to loss or severe reduction of mutant transcript levels by NMD
[Freischmidt et al., 2015; Gijselinck et al., 2015; Pottier et al., 2015],
which we additionally confirmed in the present study (Fig. 1A
and B). Further, we detected two splice donor-site mutations. The
c.1340+1G>A in intron 11 leads to out-frame skipping of exon 11
and the introduction of a PTC (p.Ala417∗). Exon 11 skipping by this
mutation was previously demonstrated by Freischmidt et al. (2015)
and was identified in five Swedish individuals: three sporadic ALS
patients, one familial ALS patient, and one unaffected individual
with a family history of ALS. Interestingly, the FTD patient in whom
we identified the same p.Ala417∗ mutation was also of Swedish ori-
gin, potentially indicative of a founder mutation. In a Belgian FTD
patient, we identified the c.992+1G>T mutation in the consensus
splice donor sequence of intron 8 and demonstrated activation of a
cryptic splice-site upstream in exon 8, resulting in a frameshift and
30%–50% reduced expression in blood and brain [Gijselinck et al.,
2015]. In addition to these 11 proven protein-truncatingmutations,
we detected two additional splice donor-site mutations in intron
3 (c.228+1G>A) and intron 8 (c.992+4 7delAGTA) (Table 2). Both
are predicted to lead to in-frame skipping of their respective exons.
Unfortunately, no biomaterials of the carriers were available to
investigate potential cryptic splicing or the formation of unsta-
ble/nonfunctional protein due to the loss of conserved amino acid
sequence; therefore, their pathogenic effect remains speculative.
In addition to TBK1 protein-truncating mutations, we identified
eight carriers of three in-frame amino acid deletions: p.Thr79del,
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p.Asp167del, and p.Glu643del (Table 2). For p.Thr79del and
p.Glu643del, we demonstrated a near total loss of mutant protein
in vivo and partial loss in vitro, likely due to protein instability
[Gijselinck et al., 2015] (Fig. 1D; Supp. Fig. S1). In contrast, this
was not the case for p.Asp167del for which TBK1 protein expres-
sion was preserved [Gijselinck et al., 2015] (Supp. Fig. S1). Yet, total
(p.Thr79del and p.Asp167del) or highly reduced (p.Glu643del) loss
of TBK1 autophosphorylation and NFκB activation was measured
for all threemutations. Therefore, the observed effects of p.Thr79del
and p.Glu643del on autophosphorylation and on NFκB activation
might also result from reduced activity of the remaining mutant
protein, in addition to reduced protein expression. The deleterious
effect of p.Asp167del was to be expected since Asp167 is located
in the activation loop of the KD, of which phosphorylation is re-
quired for TBK1 activation [Larabi et al., 2013]. Also, p.Thr79del
and p.Glu643del affect highly conserved amino acids andmap to the
catalytic KD and the SDD, located further downstream. TBK1 is a
multifunctional kinase, phosphorylating a wide range of substrates,
including theNFkB complex. Importantly, as indicated above, TBK1
itself is activated by homodimerization and subsequent autophos-
phorylation. Although it is currently not known which function(s)
of TBK1 contribute to the disease mechanism(s) in FTD and ALS,
measuringNFκB induction by observedTBK1mutations compared
with wild-type TBK1 can serve as a first functional readout for
their effect on TBK1 function related to the NFkB pathway, await-
ing more tailored functional pathogenicity assays. In vivo, the two
mechanisms of LoF through loss-of-protein and protein function
may very well complement each other.
The largest group of mutations that we identified were missense
mutations. In total, screening of 2,538 patients and 2,183 control in-
dividuals revealed 40 missense mutations, spread over the different
proteindomains andobservedboth inpatients andcontrols (Table 3;
Fig. 2). Using the NFκB reporter assay, we were able to discriminate
10 functional missense mutations that abolished or significantly
reduced NFκB activation. Functional missense mutations mainly
clustered in the KD, with only one exception for the p.Ile418val mu-
tation located in the SDD, and most likely exert their effect through
a defect in the catalytic kinase activity of TBK1. These functional
missense mutations are possibly pathogenic, although their degree
of pathogenicity may be variable, correlating with a complete ab-
sence of TBK1 activity for some to a significant reduction of50%,
or more for others (Fig. 2). The p.Leu94Ser mutation was a bit par-
ticular compared to the other functional missense mutations as it
showed reduced protein expression, probably due to unstable pro-
tein (Supp. Fig. S1). The loss of NFκB activation by this mutation
might therefore result from a combination of both loss-of-protein
and protein function, similar to what was observed for some in-
frame single amino acid deletions. For three missense mutations,
one patient-specific c.217A>G (p.Ile73Val) and two control-specific
c.149A>C (p.Asp50Ala) and c.1364A>G (p.Asn455Ser), the NFκB
reporter assay measured a significant increase in activity (Table 3;
Fig. 2). The biological relevance of these observations is not clear;
however, an increase in TBK1 activity does not seem relevant in the
context of a LoF disease mechanism, and most likely these missense
mutations are neutral with respect to ALS and FTD.
Even though occasional functional missense mutations were ob-
served in the healthy study population (4/2,183, 0.18%), twice as
many were present in patients (8/2,538, 0.32%). In other words,
of the 12 carriers of a functional missense mutation, eight (67%)
were diagnosed with ALS or FTD. When we looked specifically at
missense mutations that were only observed in patients, 44% (7/16)
had a compromised NFκB activation capacity compared with 12%
(5/41) of the missense mutations observed in controls, which was
statistically significant (P = 0.025). The observed enrichment of
functional TBK1 missense mutations in patients suggests that they
may function as high-risk alleles through various degrees of loss-of-
protein function.
Mutations in the KD affect the catalytic domain and likely affect
phosphorylation of all targets. As such, the NFκB activation assay
may be considered a valid test of pathogenicity because it measures
the kinase activity, independent of substrate. However, we cannot
exclude that additional missense mutations with no assessable ef-
fect on the NFκB/IFN pathway may be pathogenic. Other pathways
may be affected by hampered binding or phosphorylation of the
respective substrates. Indeed, for at least one additional missense
mutation, c.1717C>G (p.Arg573Gly) located in the SDD, we have
evidence for cosegregation in four affected sibs, suggestive of an
autosomal-dominant inheritance. This sib-ship presented with a
heterogeneous disease presentation of FTD, AD-type dementia, and
MND (Go´mez-Tortosa, Submitted). Mutations in other domains,
such as the C-terminal substrate-binding domain, may selectively
affect specifickinase activities, and therefore theNFκBassaymaynot
be a good readout for pathogenicity for these mutations, depend-
ing on which TBK1 functions are central to disease. As proposed
by Freischmidt (2015), loss of OPTN binding may be sufficient to
cause ALS and FTD [Freischmidt et al., 2015]. To further investigate
the possibility that some of the observed missense mutations had
an effect on OPTN binding, we modeled the missense mutations
of the patient and control fraction outside the KD by OPTN coim-
munoprecipitation. The missense mutations under study did not
show any evidence for reduced OPTN binding (data not shown).
Since TBK1 operates as a homodimer, pathogenic TBK1 missense
mutations, regardless of which domain they are located in, may in
addition also have a dominant-negative effect by competing with
wild-type TBK1.
Mean onset age in the 19 TBK1 LoF mutation carriers (protein-
truncating mutations + in-frame deletions) was 63.9 ± 7.8 years
(range48–78).Remarkable in termsof survivalwas thehuge range in
disease duration from 6 to 136 months. In terms of phenotypic het-
erogeneity, one patient (p.Lys29Argfs∗15) showed a clinically mixed
picture of behavioral disturbances (bvFTD), PNFA, and symmetric
Parkinsonian syndrome of bilateral rigidity, hypokinesia, vertical
gaze paresis, and gait disorder, suggestive for progressive supranu-
clear palsy. Patient (p.Trp445∗)was diagnosedwithCBS andnonflu-
ent/agrammatic variant PNFA. Neuropathological examination of
the FTLD-ALS patient with the p.Thr79del mutation showed a tem-
poral accentuated brain atrophy with abundant neuronal and glial
TDP-43 protein aggregates, with upper and lowermotor neuron in-
volvement, and AgD in the medial temporal lobe. The concomitant
AgD probably contributed to the lobar atrophy and to the clini-
cal picture of this patient. AgD has clinically been related to mild
forms of dementia withmood and behavioral disturbances, person-
ality changes, aggressiveness, and even psychosis. AgD pathology
is considered to occur more frequently in aged than in younger
individuals [Pham et al., 2011], and has also been detected in cog-
nitively normal subjects. Moreover, AgD has been described in as-
sociation with several other neurodegenerative conditions. Coinci-
dental TDP-43 protein aggregates in the medial temporal lobe have
been repeatedly reported to occur relatively frequently in associa-
tion with AgD [Fujishiro et al., 2009; Arnold et al., 2013]. Therefore,
the co-occurrence of FTLD-TDP and AgD in this relatively young
(age at death 58 years) patient may suggest some—sporadic or
mutation-driven—link between abnormal Tau and TDP-43 protein
deposition.
The absence of a documented family history in 42% (8/19)
of the LoF mutation carriers underscores the marked reduced
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clinical penetrance of TBK1 mutations. This reduces penetrance,
which has also been confirmed in multigenerational families seg-
regating a TBK1 LoF mutation [Freischmidt et al., 2015; Gijselinck
et al., 2015; Van Mossevelde et al., 2015], explains why apparently
sporadic patients carry a Mendelian TBK1 mutation. In these pa-
tients, family history may be obscured due to small family size or
pleiotropic manifestation of TBK1 mutations as FTD or ALS. In-
quiry of family history in isolated FTD patients may not take into
account relatives with motor neuron symptoms and, vice versa, in
ALS patient’s relatives with cognitive problems. Reduced penetrance
and observation ofMendelianmutations in apparently sporadic pa-
tients or isolated patients is also a recurring theme in other major
Mendelian genes in FTD and ALS, such as GRN (MIM# 138945)
and C9orf72. We previously showed that 50% of TBK1 carriers are
affected by the age of 70 [Van Mossevelde et al., 2015]. In the ex-
tended set of 19 TBK1 LoF carriers from this study, just one patient
was affected by the age of 50 (5%), six by the age of 60 (32%),
and 16 by the age of 70 years (84%). It is noteworthy that in the
carriers of a functional missense high-risk variant, average onset
age of 46.6 ± 7.4 years (range 34–57) was markedly lower than in
the group of LoF mutations. Two of the TBK1 missense variant
carriers also carried a C9orf72 repeat expansion. Interestingly, the
patient with the TBK1 c.731G>T (p.Gly244Val) mutation shown to
attenuate NFκB induction in combination with aC9orf72 repeat ex-
pansionhad apronounced early disease onset of 41 years.We already
described this patient when we identified the C9orf72 repeat expan-
sion in FTD-ALS spectrum patients [van der Zee et al., 2013]. Her
disease course was characterized by rapidly progressive FTD with
bulbar ALS and death after 2 years [Chester et al., 2013]. In con-
trast, the other C9orf72 expansion carrier with the TBK1 c.550A>G
(p.Met184Val) mutation without effect on the NFκB activation had
an onset age of 70 years. Considering the high prevalence ofC9orf72
repeat expansions in FTD-ALS spectrum patients, it is not surpris-
ing that in some patients amutation inTBK1,GRN, or another gene
can co-occur with a C9orf72 repeat expansion that may influence
disease penetrance.
In conclusion, we investigated a large European study population
of 2,538 European FTD-ALS spectrum patients to get a deeper ap-
preciation of the mutation frequency, mutation spectrum, and the
genotype–phenotype profile ofTBK1 patient carriers. In addition to
the typical LoF protein-truncatingmutations, we demonstrated that
in-frame amino acid deletion mutations and a significant fraction
of the missense mutations, particularly those mapping to the kinase
domain, also lead to loss-of-protein and/or protein function.Weob-
served a mutation frequency for TBK1 LoF protein-truncating and
in-frame deletionmutations of 0.7%, representing 0.4% in the FTD,
1.3% in the ALS, and 3.6% in the FTD-ALS clinical subgroups. Tak-
ing also the functional missense high-risk alleles into account, mu-
tation frequencies increased to 1.1% overall and 0.6% in FTD, 2.0%
in ALS, and 4.5% in FTD-ALS patients. These mutation frequencies
are relatively low compared with other FTD-ALS spectrum genes
likeC9orf72. Nevertheless, the highermutation frequencies in FTD-
ALS and in ALS patients warrant diagnostic testing. Furthermore,
as indicated above, calculated TBK1mutation frequencies may still
be an underestimation with a substantial fraction ofmissensemuta-
tions remaining unresolved. Although TBK1 is a well-characterized,
multifunctional kinase,whichof theTBK1 functions that specifically
contribute to the diseasemechanism in FTD andALS are poorly un-
derstood. Hopefully, in the years to come, more functional data will
become available, and based on this information, better informed
and targeted pathogenicity assays or biomarkers can be developed
for more reliable risk prediction and counseling in TBK1mutation
carriers.
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